Roche struck an exclusive global licensing agreement with Simcere Zaiming for SIM-0660, a preclinical trispecific T-cell engager targeting CD79a, CD19, and CD3, with up to $1.53 billion in total potential payments. Roche will fund development, manufacturing, and commercialization, while Simcere becomes eligible for an upfront fee plus development, regulatory, and sales milestones. The deal reflects continued appetite for next-generation TCEs designed to drive potent T-cell killing while managing cytokine release risks that have complicated earlier CD3-engager approaches. SIM-0660 is built on Simcere’s TCE platform and is positioned for B-cell-mediated diseases including lymphoma and autoimmune indications. For Roche, the transaction plugs a B-cell-targeting gap and strengthens its immunology pipeline through an asset still in IND-enabling stages—maintaining the company’s emphasis on antibody-sized structures that can reconfigure immune cell engagement mechanisms.